Trial Profile

Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study

Status: Withdrawn prior to enrolment

Phase of Trial: Phase IV

Latest Information Update: 14 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dolutegravir (Primary) ; Lamivudine (Primary)
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms PADDLE184V

Most Recent Events

05 Apr 2022 Planned End Date changed from 1 Aug 2022 to 30 Aug 2022.
05 Apr 2022 Status changed from suspended to withdrawn prior to enrolment due to low recruitment since did not find participants with the M184V mutation which is an inclusion criteria.
30 Mar 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com